FLINT, Mich. — The board of directors of Diplomat Pharmacy has appointed Brian Griffin board chairman and chief executive officer, effective June 4, the company announced last month. Griffin recently resigned as the executive vice president and CEO of IngenioRx, the pharmacy benefit manager of Anthem Inc.
“We are pleased to welcome Brian to the Diplomat team at this important time and are confident that his dynamic skill set and significant industry experience make him ideally suited to assume the roles of CEO and chairman,” said Ben Wolin, who was serving as the chairman of Diplomat’s board. “Brian is a proven health care executive, having served in various leadership roles for many years, including at Express Scripts, Empire BlueCross BlueShield and Anthem, most recently launching its PBM organization. He brings expertise in areas essential to Diplomat’s continued growth and success, including a tremendous knowledge of the PBM and specialty pharmacy industries and a deep understanding of the complexities and trends shaping the health care environment. His deep experience in health plan leadership will be instrumental in leading Diplomat in the rapidly evolving health care environment. On behalf of my fellow board members, we look forward to the next stage of the company’s growth under Brian’s leadership and are enthusiastic about the opportunities ahead.”
Griffin also served as executive vice president and president of Anthem’s commercial and specialty business division. He joined Anthem in 2013 as president and CEO of the company’s second-largest affiliated health plan, Empire BlueCross BlueShield.
“This is a time of great opportunity for Diplomat, and I have long admired the company and its innovative approach to driving better health outcomes,” Griffin said. “Following years of leadership experience in the health care industry, I feel both ready and honored to take on the roles of CEO and chairman of Diplomat. Together with the board and management team, I look forward to furthering Diplomat’s growth strategy as we enhance value for shareholders and help enable increased benefits for physicians, pharma, payers and patients.”